XM006

XM006 is a preclinical-stage drug candidate being developed by Hefei Xingmou Biotechnology (also known as StarryGene) for the treatment of arthritis. Developed by a company primarily focused on ophthalmic gene therapies, XM006 represents an expansion of their pipeline into musculoskeletal diseases. As of early 2024, the program is in the activity validation and preclinical research phase. While the specific biological target and molecular structure have not been publicly disclosed, the developer's core technological platform is centered on gene therapy. The drug is intended to address therapeutic needs in the area of skin and musculoskeletal diseases, specifically targeting arthritis indications.